Recursion Pharmaceuticals (RXRX) reported a Q4 loss Friday of $0.53 per diluted share, widening from a loss of $0.42 a year earlier.
Analysts polled by FactSet expected a loss of $0.38.
Revenue for the quarter ended Dec. 31 was $4.5 million, down from $10.9 million a year earlier.
Analysts surveyed by FactSet expected $15.3 million.
The biopharmaceutical company said it held cash, cash equivalents, and restricted cash of $603.0 million as of Dec. 31, compared with $401.4 million a year earlier, giving it a runway to extend into 2027.
Shares of the company were down 12% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。